Dassault Systemes eyes life science boost with $5.7B Medidata buy

New York City
New York-based biopharma services company Medidata Solutions will help boost Dassault Systemes' life science ambitions. (Pixabay)

Clinical trial specialist Medidata Solutions is being bought out by France’s Dassault Systemes in a $5.7 billion deal designed to help the tech firm diversify deeper into the biopharma services world.

The cash deal sees the New York-based company subsumed into Dassault, which has specialized in design software but now wants in on the lucrative CRO and clinical trial space that has seen a bunch of high-end deals and buyouts in recent years.

“This is by far the largest acquisition we’ve ever made,” Pascal Daloz, chief financial officer of Dassault, said on a conference call and quoted in Fortune.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Medidata, which had sales of $636 million last year, has been making its own deals over the years, including pacts with biotechs such as Forty Seven. In 2017, it inked a deal centered on site payments for Worldwide Clinical Trials after the biopharma services company spent 18 months looking for the right partner.

Last summer, Big Pharma giant Novartis also penned a deal with Shyft, a Medidata subsidiary, to help strengthen its digital solutions and help it push on with the launch of new therapies targeted for the European market.

Back in 2016 it also made its own buyout, snapping up Intelemage and integrating its medical image sharing technology into its cloud-based clinical trial platform.

Suggested Articles

GenapSys has unveiled its compact, high-throughput DNA sequencer, alongside a $90 million venture capital raise to help jump-start its launch.

LivaNova plans to restructure its heart valve operations, and will drop its investigational Caisson transcatheter mitral valve replacement altogether.

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.